Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Perrigo Company (PRGO) and Abbott Laboratories (ABT)

Tipranks - Tipranks - Fri Oct 17, 2025

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Align Tech (ALGN – Research Report), Perrigo Company (PRGO – Research Report) and Abbott Laboratories (ABT – Research Report).

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Align Tech (ALGN)

UBS analyst Kevin Caliendo maintained a Hold rating on Align Tech today and set a price target of $155.00. The company’s shares closed last Wednesday at $128.43.

According to TipRanks.com, Caliendo is a 3-star analyst with an average return of 4.2% and a 55.8% success rate. Caliendo covers the Healthcare sector, focusing on stocks such as Lifestance Health Group, Solventum Corporation, and Quest Diagnostics. ;'>

Currently, the analyst consensus on Align Tech is a Moderate Buy with an average price target of $170.75, representing a 30.6% upside. In a report issued on October 10, Jefferies also downgraded the stock to Hold with a $140.00 price target.

See today’s best-performing stocks on TipRanks >>

Perrigo Company (PRGO)

In a report released today, Chris Schott from J.P. Morgan maintained a Buy rating on Perrigo Company, with a price target of $32.00. The company’s shares closed last Wednesday at $21.38.

According to TipRanks.com, Schott is a 3-star analyst with an average return of 1.8% and a 51.3% success rate. Schott covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals, Bristol-Myers Squibb, and Elanco Animal Health. ;'>

Perrigo Company has an analyst consensus of Moderate Buy, with a price target consensus of $31.00.

Abbott Laboratories (ABT)

In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Abbott Laboratories, with a price target of $145.00. The company’s shares closed last Wednesday at $129.45.

According to TipRanks.com, Marcus is a 4-star analyst with an average return of 8.1% and a 52.0% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Inspire Medical Systems, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Laboratories with a $146.59 average price target, a 14.5% upside from current levels. In a report issued on October 10, Benchmark Co. also initiated coverage with a Buy rating on the stock with a $145.00 price target.

Read More on ALGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).